Related Experiment Video

Updated: Mar 13, 2026

Disrupting Reconsolidation of Fear Memory in Humans by a Noradrenergic β-Blocker
08:32

Disrupting Reconsolidation of Fear Memory in Humans by a Noradrenergic β-Blocker

Published on: December 18, 2014

23.5K

[Neonatal use of propranolol for segmental facial hemangiomas]

V Villamil1, N A Méndez Aguirre1, T Martínez Menchón2

  • 1Servicio de Cirugía Pediátrica. Hospital Clínico Universitario Virgen de la Arrixaca, Murcia.

Cirugia Pediatrica : Organo Oficial De La Sociedad Espanola De Cirugia Pediatrica
|October 25, 2016
PubMed

Insights

Neonatal segmental facial hemangiomas treated with propranolol showed complete involution without adverse effects. This study supports early propranolol use in newborns for effective and safe hemangioma management.

Area of Science:

  • Pediatric Dermatology
  • Neonatal Care
  • Vascular Malformations

Background:

  • Segmental cervico-facial hemangiomas are large vascular lesions (>5 cm) affecting specific facial areas.
  • These lesions can be associated with PHACE syndrome, a complex of malformations.
  • Limited data exists on the efficacy and safety of propranolol for neonatal hemangioma treatment.

Observation:

  • Four neonates with segmental facial hemangioma received propranolol treatment.
  • Three of the four patients were diagnosed with PHACE syndrome.
  • Adverse effects were monitored during the initial hospital admission.

Findings:

  • Propranolol demonstrated 100% efficacy in all treated patients.
  • Complete hemangioma involution was observed in all cases.
  • No adverse effects were reported during neonatal treatment with propranolol.

Implications:

  • Neonatal propranolol therapy is effective and safe for segmental facial hemangiomas.
  • Early initiation of propranolol, under hospital surveillance, is recommended.
  • Weighing the benefits against risks supports using the lowest effective propranolol dose for improved outcomes.
Abstract

Keywords:
HemangiomaNeonatalPHACEPropranolol

More Related Videos

A Modified Sonographic Algorithm for Image Acquisition in Life-Threatening Emergencies in the Critically Ill Newborn11:27

A Modified Sonographic Algorithm for Image Acquisition in Life-Threatening Emergencies in the Critically Ill Newborn

Published on: April 7, 2023

7.7K
Transcutaneous Microcirculatory Imaging in Preterm Neonates06:27

Transcutaneous Microcirculatory Imaging in Preterm Neonates

Published on: December 31, 2015

8.6K

Related Concept Videos

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
1.9K
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
1.3K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
578
Mitral Stenosis III: Medical Management01:26

Mitral Stenosis III: Medical Management

Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
408
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
1.9K
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
2.2K